Rheumatoid arthritis (RA) is a chronic inflammatory disorder that principally attacks synovial joints. It is one of the most common autoimmune diseases affecting people of all ages and races. RA affects the lining of joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. It also leads to stiffness, and redness in the joints. The main factor causing rheumatoid arthritis remains unknown. However, according to studies around the world some of the genetic and environmental factors are found to be more probable causers.
Treatment of Rheumatoid Arthritis involves frequent drugs administration as RA is a progressive and incurable disease. Drugs used for treatment of RA are classified as first line agents- consisting of non steroidal anti-inflammatory drugs (NSAIDs) and steroids such as glucocorticoids and second line agents- consisting of disease modifying anti-rheumatic drugs such as chloroquine, gold salts, penicillamine, cyclosporine, and several biological agents like TNF-
Scope of the report
The report titled Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2013-18). Further, key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report.
- Abbvie Inc.
- Amgen Inc.
- Johnson & Johnson
- Roche Holdings AG